Now showing items 11-20 of 32
Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU)
(Kluwer Academic Publishers; Springer Science+Business Media, 2002-02)
Purpose: 5-Fluoro-Pyrimidinone (5FP)is an oral pro-drug of 5-Fluorouracil(5FU), and is converted to 5FU by hepaticaldehyde oxidase. Preclinically, 5FPdemonstrated anti-tumor activity againstcolon 38 and P 388 leukemia ...
Interaction between gemcitabine and mitomycin-C in vitro
(Springer-Verlag; Springer-Verlag Berlin Heidelberg, 2000-01)
Both gemcitabine (2′,2′-difluorodeoxycytidine; dFdCyd) and mitomycin-C (MMC) are active against several solid malignancies. dFdCyd is an attractive agent for use in combination with drugs which damage DNA and with radiation ...
A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study
(Kluwer Academic Publishers; Springer Science+Business Media, 2002-02)
Malignant melanoma is rapidly increasing inthe United States. Metastatic diseaseresponds poorly to currently availablechemotherapy. Pyrazine diazohydroxide(PZDH) is a new agent inhibiting DNAsynthesis that is active in ...
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)
(Kluwer Academic Publishers; Springer Science+Business Media, 2005-01)
JM-216 is an orally bioavailable platinum compound with activity against many tumor models. The objective of this study was to determine the safety profile and anti-tumor activity of JM-216 in patients with hormone refractory ...
A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
(Kluwer Academic Publishers; Springer Science + Business Media, Inc., 2005-12)
Background . Pancreatic cancer is amongst the most chemoresistant malignancies. Expression of the cyclooxygenase-2 (COX-2) enzyme plays a major role in tumor progression and resistance to therapy. A Phase II study was ...
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
(Kluwer Academic Publishers; Springer Science+Business Media, 2004-11)
Objectives : CCI-779 is an ester of the immunosuppressive agent sirolimus (rapamycin) that causes cell-cycle arrest at G1 via inhibition of key signaling pathways resulting in inhibition of RNA translation. Antitumor ...
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
(Kluwer Academic Publishers; Springer Science + Business Media, Inc., 2005-08)
Purpose : Loss of PTEN, which is common in glioblastoma multiforme (GBM), results in activation of the mammalian target of rapapmycin (mTOR), thereby increasing mRNA translation of a number of key proteins required for ...
Hydroxyapatite implants with designed internal architecture
(Kluwer Academic Publishers; Springer Science+Business Media, 2001-06)
Porous hydroxyapatite (HA) has been used as a bone graft material in the clinics for decades. Traditionally, the pores in these HAs are either obtained from the coralline exoskeletal patterns or from the embedded organic ...
A Phase I Clinical Trial of Spicamycin Derivative KRN5500 (NSC 650426) Using a Phase I Accelerated Titration “2B” Design
(Kluwer Academic Publishers; Springer Science+Business Media, 2003-02)
The spicamycin derivative KRN5500 was considered as a potential anti-cancer agent based on in vitro and preclinical studies. A Phase I study involving 24 cancer patients in whom tumors were refractory to all other conventional ...
Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study
(Kluwer Academic Publishers; Springer Science+Business Media, 2004-01)
Purpose : Experimental data, both in vivo and in vitro , suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this ...